Investor Presentation First Nine Months of 2022
27
Investor presentation First nine months of 2022
Novo NordiskⓇ
Novo Nordisk's core capabilities provide a competitive advantage
to continue to defeat diabetes
Engineering, formulating,
developing and delivering
protein-based treatments
L
Efficient large-scale
production of proteins
السمر
Global commercial reach and
leader in chronic disease care
Deep disease
understanding
Today: Oral solutions to
differentiate from
competition
Tomorrow: Expand oral
platforms and transformational
medicines via Novo Nordisk stem
balo
Today: The world's
largest producer of
insulin and GLP-1
Tomorrow: Expand capacity and
continue efficiency gains
|.000
५
Today: Global reach and
OzempicⓇ was the fastest
blockbuster in diabetes
Tomorrow: Continued rollout of
portfolio and launch of new
products
D
Today: Provide value and
outcomes beyond HbA1c
for diabetes
Tomorrow: Normalise living with
diabetes supported by digital
solutions
cell platform
API: Active pharmaceutical ingredient; HbA₁: Refers to glycated haemoglobin, which is the average blood glucose (sugar) levels for the last three monthsView entire presentation